Chronic obstructive pulmonary disease
Conditions
Interventions
Traditional Chinese medicine treatment group:TCM syndrome differentiation andWestern medicine placebo
Western medicine treatment group:Western medicine treatment (theophylline zyban) and TCM syndrome differentiation liquid( aplacebo)
Sponsors
China-japan friendship hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients were included in the study according to the following: 1. patients met the diagnostic criteria; 2. patients met the TCM pattern criteria of stable COPD (TCM diagnosis); 3. patients were stable and met the diagnosis of mild to severe COPD (Global Initiative for Chronic Obstructive Lung Disease, GOLD 1,2,3); 4. patients were aged between 18 to 80 years; 5. patients underwent a two-week wash-out period prior to randomization; 6. patients had no experience in other interventional trials in the previous 1 month; and 7. patients should receive the treatment voluntarily and sign informed consent.
Exclusion criteria
Exclusion criteria: Patients were excluded from the study for the following reasons: 1. acute exacerbation of COPD or very severe COPD (GOLD 4); 2. female patients were in pregnant or breast-feeding; 3. confusion, dementia or any type of mental illness that rendered patients unable to understand the nature, scope and possible consequences of the study; 4. patients were complicated by severe heart failure (Grade II or IV New York Heart Association [NYHA] Functional Classification); 5. patients were complicated with bronchial asthma, bronchiectasis, active tuberculosis, pulmonary embolism or diffuse panbronchiolitis; 6. patients were complicated with a neuromuscular disorder, which affected the respiration; 7. patients with serious hepatic and renal diseases, such as liver cirrhosis, portal hypertension, bleeding of varicose veins, dialysis, or renal transplantation; 8. congenital or acquired immune deficiency; 9. participation in other clinical intervention research; and 10. allergies to treatment drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lung function;Blood gas analysis;symptoms;The number of exacerbations;6 min walking test;SF-36;Adverse events; | — |
Countries
China
Contacts
Public ContactLi youlin
Outcome results
None listed